Close

Building biotech in Ohio, You can if you think you can

Jul 13 2001
We are still a young industry, but we have grown-up issues.

Statement of J. Craig Venter, PhD, President, Celera Genomics

Jul 11 2001
On Behalf of the Biotechnology Industry Organization Before the Subcommittee on Consumer Protection, U.S. House Committee on Energy and Commerce.

House Energy and Commerce Committee Testimony

Jun 20 2001
By Thomas Okarma, CEO, Geron, Subcommittee on Health

Testimony of Thomas Okarma, PhD, MD President and CEO of Geron Corporation On Behalf of Biotechnology Industry Organization (BIO) Before the Subcommittee on Crime, House Judiciary Committee

Jun 19 2001
By Thomas Okarma, CEO, Geron, Subcommittee on Crime

Prescription Drug Benefits as Part of Medicare Modernization

May 10 2001
The Biotechnology Industry Organization (BIO) supports amendment of the current reexamination authority to enhance patent quality.

Letter to Mr. Nicholas Godici

May 4 2001

Acting Undersecretary of Commerce and Acting Director of the United States Patent and Trademark Office Regarding Patent Law Harmonization

Testimony of Carl B. Feldbaum Before the Senate Commerce Committee Subcommittee on Science, Technology and Space

May 2 2001
By Carl B. Feldbaum, President, BIO, Subcommittee on Science, Technology and Space

PTO response to Carl Feldbaum on International Patent Harmonization Efforts

May 1 2001

Disclosure of Information

Apr 18 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and Information Related to Human Gene Therapy or Xenotransplantation." 66 Fed. Reg. 4688 (January 18, 2001) (the Proposed Rule or FDA’s Proposal).

BIO comments on FDA proposed rule regarding disclosure of certain information in gene therapy and xenotransplantation experiments

Apr 18 2001
he Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and Information Related to Human Gene Therapy or Xenotransplantation." 66 Fed. Reg. 4688 (January 18, 2001) (the Proposed Rule or FDA’s Proposal).